An interventional study of Intranasal dexmedetomidine and Normal Saline in Coronary Heart Disease and Coronary Artery Disease, sponsored by Second Affiliated Hospital, Zhejiang University, School of Medicine. Not yet recruiting at 1 site in China. Open to participants aged 45 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-09-29.
Sponsored by Second Affiliated Hospital, Zhejiang University, School of Medicine · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 543 studies in Coronary Artery Disease with a site in China — 176 open to participants now, 210 under way, 6 of them phase 3. Coronary Artery Disease · China.
Among the 543 studies in Coronary Artery Disease with a site in China, this one is the 33rd largest by planned enrollment of the 324 interventional ones that give a count, is one of 55 that started in 2026, is one of 210 with no phase, reaches primary completion later than 183 of the 209 other live ones, and was the 531st registered.
4,862 studies on the registry are indexed under Coronary Artery Disease; 893 are open to participants now.
Browse Coronary Artery Disease studies →176 of the 543 studies in Coronary Artery Disease with a site in China are open now. Recruiting first, the newest first:
Nanjing First Hospital, Nanjing Medical University · Sites in China
Ages 18–80
BrosMed Medical Co., Ltd · Sites in China
Ages 18+
China National Center for Cardiovascular Diseases · Sites in China
Ages 18+
Ruijin Hospital · Sites in China
Ages 18+
Beijing Inno Medicine Co., Ltd. · Sites in China, United States, Australia and 1 more country
Ages 18–80
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 589 Coronary Artery Disease studies recruiting now, 403 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 38 take children under 18; 48 take healthy volunteers.
This study: 45 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
543 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 25 · Phase 3 24 · Phase 4 66
First in 2000; this study’s year is marked. 55 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 2,500 is above the median of 124 across 3,009 interventional studies indexed under Coronary Artery Disease.
Median enrollment 307 across the 324 interventional studies, 720 across the 218 observational. Of the 187 that completed or were terminated, 24 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
110 of 543 have an industry lead sponsor. The 10 most frequent:
Second Affiliated Hospital, Zhejiang University, School of Medicine is the lead sponsor of 100 studies on the registry; 68 are open to participants now.
Second Affiliated Hospital, Zhejiang University, School of Medicine has 4 studies filed under Coronary Artery Disease — fewer than ten, so there is no comparison to draw.
33 of the studies in Coronary Artery Disease with a site in China that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05175274Phase 3Qingdao Central HospitalColchicine Use for Primary Prevention of Coronary Artery Disease | 2027-03-01 |
| NCT07439133Phase 3Sinotau Pharmaceutical GroupComparison of Diagnostic Accuracy Between XTR004 PET MPI and the Composite Index of Quantitative Coronary Angiography (QCA) and Fractional Flow Reserve (FFR) | 2027-06 |
| NCT05638867China National Center for Cardiovascular DiseasesNOAC Therapy Guided by PARIS Risk Score and D-dimer in Patients With ACS After PCI | 2026-12 |
| NCT06845410Peking Union Medical College HospitalClinical Features, Current Treatment and Clinical Outcomes in Patients With INR-CAD: a Cohort Study | 2026-12 |
| NCT06917664China National Center for Cardiovascular DiseasesTreatment of Moderate Ischemic Mitral Regurgitation in Patients With Coronary Artery Disease | 2026-12 |
Add all 33 to your calendar (.ics) → With an account.
Among the 543 studies in Coronary Artery Disease with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to determine the effect of pre-operative dexmedetomidine on periprocedural myocardial injury in patients having percutaneous coronary intervention (PCI). The specific research hypothesis is that intranasal administration of 100 μg dexmedetomidine (DEX) reduces the incidence of periprocedural myocardial injury within 48 hours after PCI, as compared with normal saline.
Participants will be randomly assigned in a 1:1 ratio to two groups: the dexmedetomidine group and the placebo group.
4,862 studies on the registry are indexed under Coronary Artery Disease; 893 are open to participants now.
This study's planned enrollment of 2,500 is above the median of 124 across 3,009 interventional studies indexed under Coronary Artery Disease.
Browse Coronary Artery Disease studies →Second Affiliated Hospital, Zhejiang University, School of Medicine is the lead sponsor of 100 studies on the registry; 68 are open to participants now.
Compared within Coronary Artery Disease, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Coronary Disease. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will receive intranasal DEX (100 μg) 60 ± 10 minutes before the procedure in the preoperative preparation area, with the solution equally sprayed into both nostrils (two sprays per nostril).
Drug: Intranasal dexmedetomidine
Patients will receive an equal volume of intranasal normal saline containing no active ingredient 60 ± 10 minutes before the procedure.
Drug: Normal Saline
Patients will receive intranasal DEX (100 μg) 60 ± 10 minutes before the procedure in the preoperative preparation area, with the solution equally sprayed into both nostrils (two sprays per nostril).
Patients will receive an equal volume of intranasal normal saline containing no active ingredient.
Myocardial injury occurring within 48 hours after surgery
In patients with a normal baseline cardiac troponin (cTn, whether non-high sensitivity cTnT or cTnI) concentration (≤99th percentile upper reference limit \[URL\]), postoperative cTn elevation exceeding the 99th percentile URL. In patients with an elevated baseline cTn concentration (\>99th percentile URL) that was stable or decreasing, a postoperative cTn increase of \>20% from baseline, with an absolute value exceeding the 99th percentile URL
Time frame: Within 48 hours after surgery
Delirium within the first postoperative day
The 3D-CAM scale will be used to evaluate participants for postoperative delirium.
Time frame: Within the first postoperative day
Acute kidney injury in 48 hours after PCI
An absolute increase in serum creatinine of ≥0.3 mg/dL within 48 hours after PCI, or a relative increase in serum creatinine of ≥50% within 7 days after PCI
Time frame: Within 48 hours after PCI.
A collapsed (one or more) composite of serious cardiovascular complications within 30 days after PCI
Components of the composite are: (1) myocardial infarction; (2) new-onset stroke or transient ischemic attack (TIA); (3) all-cause mortality; (4) any unplanned repeat revascularization; (5) arrhythmias requiring electrical or pharmacological treatment.
Time frame: Within 30 days after PCI
Postoperative first-night sleep quality
Sleep quality during the surgical night will be assessed using the Richards-Campbell Sleep Questionnaire (RCSQ) on the morning of postoperative day 1.This scale consists of 6 dimensions, each scored on a scale of 0 to 100, with higher scores indicating better sleep quality.
Time frame: Postoperative day 1.
Perioperative anxiety score
Peri-operative anxiety status will be assessed with the Perioperative Anxiety Scale-7 (PAS-7). This scale consists of 7 dimensions, each scored on a scale of 0 to 4, with higher scores indicating more severe anxiety symptoms.
Time frame: From study drug administration to 6 hours after PCI.
Peak postoperative cardiac troponin
Marker values will be standardised (multiples of the upper-reference-limit, ×URL) according to different types of cardiac biomarkers.
Time frame: Within 48 hours after PCI
Intraoperative pain score
Pain intensity assessed immediately post-procedure by Numeric Rating Scale(NRS). This scale is scored on a scale of 0 to 10, with higher scores indicating more severe pain.
Time frame: Immediately post-procedure.
The EuroQol Five-Dimensional Questionnaire (EQ-5D) scores at 30 days after PCI
Assessed by the EuroQol Five-Dimensional Questionnaire (EQ-5D) at 30 days post-PCI. The EQ-5D comprises 5 dimensions and a visual analogue scale. Each dimension is rated at 5 levels. The EuroQol visual analogue scale (EQ-VAS) requires patients to rate their current overall health on a 0-100 visual analogue scale, where 0 represents the worst health state imaginable and 100 represents the best health state imaginable.
Time frame: At 30 days post-PCI.
The Kansas City Cardiomyopathy Questionnaire (KCCQ) scores at 30 days after PCI
The KCCQ comprises 23 items across 7 domains, each scored on a scale of 0 to 100, with higher scores indicating better health status.
Time frame: At 30 days post-PCI.
Acute adverse reactions
Acute adverse reactions include allergy, dizziness, nausea, vomiting, and other related manifestations.
Time frame: Within the period from drug administration to 6 hours after surgery
Hypotension
A mean arterial pressure (MAP) below 65 mmHg or a reduction of more than 30% from baseline.
Time frame: Within the period from drug administration to 6 hours after surgery.
Severe bradycardia
A heart rate below 40 beats per minute.
Time frame: Within the period from drug administration to 6 hours after surgery.
Hypoxemia
An oxygen saturation below 90% lasting for at least 30 seconds.
Time frame: Within the period from drug administration to 6 hours after surgery.
Dosage of vasoactive agents
Vasoactive agents includes atropine, norepinephrine, and nitroglycerin.
Time frame: Within the period from drug administration to 6 hours after surgery.
Local nasal adverse reactions
Local nasal adverse reactions: including nasal discomfort, irritation, nasal congestion, rhinorrhoea, epistaxis, dysgeusia, and incomplete delivery of study nasal-spray medication.
Time frame: Within the period from drug administration to 6 hours after surgery.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Sep 2026; primary completion for Jun 2029, 33 months later.
Of 753 non-industry interventional studies with no phase under Coronary Artery Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 53. This study's planned 33 months is close to that.
Counting every sponsor, half of 930 studies reached it within 30 months; a quarter within 15 and three quarters within 50.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dexmedetomidine
Second Affiliated Hospital, Zhejiang University, School of Medicine →